Literature DB >> 10688822

Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking.

A Oda1, Y Ikeda, H D Ochs, B J Druker, K Ozaki, M Handa, T Ariga, Y Sakiyama, O N Witte, M I Wahl.   

Abstract

Stimulation of the platelet nonintegrin collagen receptor, glycoprotein VI, evokes a signaling response similar to that induced by antigen receptor activation in B and T lymphocytes. A key transducer of the lymphocyte signaling pathways is the Bruton's tyrosine kinase (Btk)/Tec kinase family, which connects receptors to the elevation of intracellular-free calcium levels. An important signaling function for Btk in collagen-induced platelet activation in vitro was recently demonstrated by other researchers using Btk-deficient platelets from patients with X-linked agammaglobulinemia (XLA). Since Btk-deficiency does not induce an overt platelet-based bleeding disorder in vivo, collagen receptor responses may include other Btk/Tec kinase family members in normal platelets. Both Btk and Tec had increased tyrosine following stimulation of collagen receptors or CD32 cross-linking. Data from kinetic analyses and inhibitor studies and the use of phosphopeptide-specific antibodies recognizing 2 Btk regulatory phosphorylated tyrosine residues suggest a mechanism for coordinate recruitment of Btk and Tec through the immunoreceptor tyrosine-based activation motif, Src family kinases, and phosphatidylinositol 3-kinase. In XLA platelets, collagen treatment increased tyrosine phosphorylation of Tec and several other signaling proteins, including Lyn, Fyb, Slp-76, and the Wiskott-Aldrich syndrome protein. This indicates that important elements of the collagen signaling pathway proximal and distal to Btk and Tec are preserved despite the lack of functional Btk. The results are consistent with the conclusion that activation of Tec may sustain XLA platelet function in vivo, while some in vitro assays of nonintegrin collagen receptor signaling through the Btk/Tec kinase family reflect the additive dosage of the transducers. (Blood. 2000;95:1663-1670)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688822

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  The Tec family kinase Itk exists as a folded monomer in vivo.

Authors:  Qian Qi; Avery August
Journal:  J Biol Chem       Date:  2009-08-28       Impact factor: 5.157

2.  Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.

Authors:  Bhanu Kanth Manne; Rachit Badolia; Carol Dangelmaier; Johannes A Eble; Wilfried Ellmeier; Mark Kahn; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2015-03-12       Impact factor: 5.157

Review 3.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

4.  Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Andrew H Lipsky; Mohammed Z H Farooqui; Xin Tian; Sabrina Martyr; Ann M Cullinane; Khanh Nghiem; Clare Sun; Janet Valdez; Carsten U Niemann; Sarah E M Herman; Nakhle Saba; Susan Soto; Gerald Marti; Gulbu Uzel; Steve M Holland; Jay N Lozier; Adrian Wiestner
Journal:  Haematologica       Date:  2015-10-01       Impact factor: 9.941

Review 5.  Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis.

Authors:  François Caron; Darryl P Leong; Christopher Hillis; Graeme Fraser; Deborah Siegal
Journal:  Blood Adv       Date:  2017-05-09

6.  Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.

Authors:  Junling Liu; Malinda E Fitzgerald; Michael C Berndt; Carl W Jackson; T Kent Gartner
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

Review 7.  Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity.

Authors:  Yacine Boulaftali; Paul R Hess; Mark L Kahn; Wolfgang Bergmeier
Journal:  Circ Res       Date:  2014-03-28       Impact factor: 17.367

8.  Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

Authors:  Luise Goldmann; Rundan Duan; Thorsten Kragh; Georg Wittmann; Christian Weber; Reinhard Lorenz; Philipp von Hundelshausen; Michael Spannagl; Wolfgang Siess
Journal:  Blood Adv       Date:  2019-12-10

9.  Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Authors:  Farrukh T Awan; Anna Schuh; Jennifer R Brown; Richard R Furman; John M Pagel; Peter Hillmen; Deborah M Stephens; Jennifer Woyach; Elena Bibikova; Prista Charuworn; Melanie M Frigault; Ahmed Hamdy; Raquel Izumi; Bolan Linghu; Priti Patel; Min Hui Wang; John C Byrd
Journal:  Blood Adv       Date:  2019-05-14

10.  Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.

Authors:  Prithviraj Bose; Varsha V Gandhi; Michael J Keating
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-11       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.